Acer Therapeutics

Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS).

The company was founded in 2013 and is headquartered in Newton, Massachusetts.

Acer Therapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $13.1B in funding across 112 round(s). With a team of 11-50 employees, Acer Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Debt - Acer Therapeutics, raised $2.1M. Discover more about their projects, partnerships, and impact on our platform.